Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fexofenadine + prednicarbate
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Oral, Topical
01
Overview
Fexofenadine + prednicarbate is a combination therapy used in the management of skin conditions associated with pruritus (itching) and inflammation, most notably atopic dermatitis. Fexofenadine is a second-generation, selective antihistamine that acts as an H1 receptor antagonist, effectively blocking the action of histamine and reducing allergic symptoms such as itching, sneezing, and urticaria. It is minimally sedating with little anticholinergic effect[2][3][5][8]. Prednicarbate is a non-halogenated, synthetic corticosteroid applied topically. It exerts local anti-inflammatory, antipruritic, and vasoconstrictive effects by suppressing the migration of polymorphonuclear leukocytes and reversing capillary permeability[4][6]. The combination is used with oral fexofenadine (typically 180 mg daily) and topical prednicarbate to improve the relief of pruritus with an acceptable safety profile in patients with atopic dermatitis and related inflammatory skin diseases[1][9].
- Other names
- fexofenadine + prednicarbate
02
Targets
GR (Glucocorticoid receptor)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on fexofenadine + prednicarbate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fexofenadine + prednicarbate.